Bavarian Nordic Announces Positive Data from Phase 2 Extension Study of its Universal RSV Vaccine
(WorldNews Denmark)

Broad antibody and T cell responses against RSV remained durable 1 year post a single vaccination with MVA-BN® RSV in the majority of subjects An annual booster of MVA-BN-RSV induced a broad and robust immune response, particularly in subjects with waning immunity one year after first vaccination, demonstrated by fast post-vaccination increases of neutralizing and total antibodies against both RSV subtypes (A & B); increases in mucosal RSV specific IgA and a broad, robust, and cellular immune response to all 5 RSV proteins encoded in the vaccine COPENHAGEN, Denmark, August 8, 2018 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today announced positive data from the extension study of its...